Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

The only US Food and Drug Administration (FDA)-approved first-line systemic therapy for hepatocellular carcinoma (HCC) is sorafenib; however, resistance or intolerance to sorafenib is unfortunately common. In this review, we briefly describe systemic therapies that can be considered for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Emily M, Sanoff, Hanna K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687453/
https://www.ncbi.nlm.nih.gov/pubmed/29184856
http://dx.doi.org/10.2147/JHC.S124366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687453/
https://www.ncbi.nlm.nih.gov/pubmed/29184856
http://dx.doi.org/10.2147/JHC.S124366

Ejemplares similares